Successsful voriconazole treatment of disseminated Fusarium infection in an immunocompromised patient

被引：63

作者：

Consigny, S

Dhedin, N

Datry, A

Choquet, S

Leblond, V

Chosidow, O

机构：

[1] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Internal Med, Paris, France

[2] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Hematol, Paris, France

[3] Hop La Pitie Salpetriere, Assistance Publ Hop Paris, Dept Parasitol Mycol, Paris, France

来源：

CLINICAL INFECTIOUS DISEASES | 2003年 / 37卷 / 02期

关键词：

D O I：

10.1086/375842

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Fusarium infection is known to cause major morbidity and mortality in immunocompromised hosts. We report the successful treatment of disseminated Fusarium infection with skin manifestations in a severely neutropenic, immunocompromised host with voriconazole, a new second-generation triazole. Voriconazole might be an alternative therapy for patients with neutropenia who have fusariosis that is refractory or unresponsive to amphotericin B or its liposomal formulation.

引用

收藏

页码：311 / 313

页数：3

相关论文

共 19 条

[1] A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients [J].

Ally, R ;

Schürmann, D ;

Kreisel, W ;

Carosi, G ;

Aguirrebengoa, K ;

Dupont, B ;

Hodges, M ;

Troke, P ;

Romero, AJ .

CLINICAL INFECTIOUS DISEASES, 2001, 33 (09) :1447-1454

[2] Fusarium, a significant emerging pathogen in patients with hematologic malignancy: Ten years' experience at a cancer center and implications for management [J].

Boutati, EI ;

Anaissie, EJ .

BLOOD, 1997, 90 (03) :999-1008

[3] Voriconazole: A second-generation triazole [J].

Chandrasekar, PH ;

Manavathu, E .

DRUGS OF TODAY, 2001, 37 (02) :135-148

[4] The combination of amphotericin B and azithromycin as a potential new therapeutic approach to fusariosis [J].

Clancy, CJ ;

Nguyen, MH .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1998, 41 (01) :127-130

[5]

Clancy CJ, 1998, EUR J CLIN MICROBIOL, V17, P573

[6] In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: Review of the literature [J].

Espinel-Ingroff, A ;

Boyle, K ;

Sheehan, DJ .

MYCOPATHOLOGIA, 2001, 150 (03) :101-115

[7]

Ghannoum MA, 2002, EUR J MED RES, V7, P242

[8] In vitro and in vivo experimental activities of antifungal agents against Fusarium solani [J].

Guarro, J ;

Pujol, I ;

Mayayo, E .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1999, 43 (05) :1256-1257

[9]

Hennequin C, 1997, J MED VET MYCOL, V35, P107

[10] Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].

Herbrecht, R ;

Denning, DW ;

Patterson, TF ;

Bennett, JE ;

Greene, RE ;

Oestmann, JW ;

Kern, WV ;

Marr, KA ;

Ribaud, P ;

Lortholary, O ;

Sylvester, R ;

Rubin, RH ;

Wingard, JR ;

Stark, P ;

Durand, C ;

Caillot, D ;

Thiel, E ;

Chandrasekar, PH ;

Hodges, MR ;

Schlamm, HT ;

Troke, PF ;

de Pauw, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415